ObiamiweUmehMDMSc.

Infectious Disease • Cambridge, MA

Transplant/Immunocompromised States

Vice- President, Clinical Development, Takeda Pharmaceutical Company

Join to view full profile

Dr. Umeh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Umeh's full profile

Already have an account?

Office
125 Binney Street
Cambridge, MA 02142
Is this information wrong?

Education & Training

Harvard Business School (Executive Education)Certificate Course, Program For Leadership Development (PLD 21), 2015 - 2016
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Infectious Disease, 2002 - 2005
Brooklyn Hospital CenterResidency, Internal Medicine, 1999 - 2002
University of Nigeria Faculty of MedicineClass of 1995

Certifications & Licensure

IN State Medical License 2001 - Present
CA State Medical License 2002 - 2026

Clinical Trials

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis Start of enrollment: 2011 Jun 20
Completed
Phase 3
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis Start of enrollment: 2011 Jun 01

Publications & Presentations

PubMed

92 citations
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled a...
Myra W. Popejoy, David L. Paterson, Daniel J Cloutier, Jennifer A. Huntington, Benjamin F. Miller, Caleb A. Bliss, Judith N. Steenbergen, Ellie Hershberger, Obiamiwe U...> ;The Journal of Antimicrobial Chemotherapy. 2017 Jan 1
32 citations
Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: res...
Jennifer A. Huntington, George Sakoulas, Obiamiwe Umeh, Daniel J Cloutier, Judith N. Steenbergen, Caleb A. Bliss, Ellie J. C. Goldstein> ;The Journal of Antimicrobial Chemotherapy. 2016 Jul 1
77 citations
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, dou...
Christopher Lucasti, Abel Jasovich, Obiamiwe Umeh, Joel Jiang, Koné Kaniga, Ian Friedland> ;Clinical Therapeutics. 2008 May 1
11 citations
Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women.
Risa M Hoffman, Obiamiwe C. Umeh, Cindy Garris, Naomi Givens, Judith S. Currier> ;HIV Clinical Trials. 2007 Nov 1
40 citations
Sex differences in pharmacokinetics and toxicity of antiretroviral therapy
Obiamiwe C. Umeh, Judith S. Currier> ;Expert Opinion on Drug Metabolism & Toxicology. 2006 Mar 24
18 citations
Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients.
Obiamiwe C. Umeh, Judith S. Currier> ;Current HIV/AIDS Reports. 2005 Aug 1
10 citations
Sex Differences in HIV: Natural History, Pharmacokinetics, and Drug Toxicity.
Obiamiwe C. Umeh, Judith S. Currier> ;Current Infectious Disease Reports. 2005 Jan 1
5 citations
Corynebacterium jeikeium sepsis after 8-methoxypsolaren photopheresis for cutaneous T-cell lymphoma
Obiamiwe Chukwudiebere Umeh, Bernard M. Kubak, David A. Pegues, Matthew Leibowitz, Larry Froch> ;Diagnostic Microbiology and Infectious Disease. 2004 Sep 1
Causes and visual outcome of childhood eye injuries in Nigeria.
Umeh, R. E., Umeh, O. C.> ;Eye (Lond). 1997
Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.
Umeh, O. C., Currier, J. S., Park, J. G., Cramer, Y., Hermes, A. E., Fletcher, C. V.> ;J Clin Pharmacol. 2011 Dec
Join now to see all